Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.

Researchers at the National Institutes of Health have found evidence that a unique type of immune cell contributes to multiple sclerosis (MS). Their discovery helps define the effects of one of the newest drugs under investigation for treating MS — daclizumab — and could lead to a new class of drugs for treating MS and other autoimmune disorders.

Health Highlights is a biweekly summary of particularly interesting articles from credible sources of health and medical information that we follow & read. For a complete list of recommeded sources, see our links page.

Following a two-and-a-half year ethics investigation, the General Medical Council (GMC), which registers doctors to practice medicine in the UK, has concluded that Andrew Wakefield, the UK researcher who suggested a link between autism spectrum disorders and MMR vaccination, acted “dishonestly and irresponsibly” in his research.

A recent study in the New England Journal of Medicine reports on two new drugs for the treatment of multiple sclerosis that are more effective than existing modalities. Vaughan Bell reviews the findings.